Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results
Q3 revenue $1.2B (+10% y/y), 2026 guidance raised to $4.775-4.85B; Xywav +12%, Ziihera launched in 1L GEA.
What this release says
Jazz reported record quarterly revenue of $1.2 billion for the third quarter of 2026, up 10% year over year, and raised its full-year 2026 total revenue guidance to $4.775 to $4.85 billion. The company also booked a $754 million acquired R&D charge from the Actio deal, which produced a net loss for the quarter. For shareholders, the revenue outlook is the positive, while the charge and the added debt weigh on the reported result.
Key figures
- Q3 2026 total revenues
- $1.2 billion
- 2026 revenue guidance
- $4.775 to $4.85 billion
- Xywav net product sales, Q3 2026
- $483 million
- Acquired IPR&D expense (ABS-1230)
- $754 million
- Long-term debt outstanding
- $5.6 billion
- Cash, equivalents and investments
- $2.9 billion
Positive for shareholders
- Total revenues rose 10% year over year to a record quarterly level.
- Xywav net product sales grew 12% with about 425 net patient additions in the quarter.
- Full-year 2026 total revenue guidance was raised.
- Board approved a new share repurchase program of up to $500 million.
Negative for shareholders
- A $754 million acquired IPR&D charge produced a GAAP and adjusted net loss for the quarter.
- Epidiolex net product sales fell 2% year over year to $295 million.
- Long-term debt totals $5.6 billion after the $1.25 billion exchangeable notes offering.
- The quarter included income tax expense, compared with a tax benefit a year earlier.
Written by Quantisnow AI from this release. Not financial advice.
Key terms
- Acquired IPR&D:
- Research and development value a company takes on when it buys another firm, recorded as an expense right away because the drug is not yet approved.
- Exchangeable senior notes:
- Debt that can be converted into shares of another company's stock, here the company's own ordinary shares, under set conditions.
- Gross-to-net deductions:
- Discounts, rebates and fees subtracted from a drug's list price to arrive at the net amount the company actually collects.
- Net patient adds:
- New patients starting a treatment minus those who stopped during the period.
FAQ
How much revenue did Jazz Pharmaceuticals report for the third quarter of 2026?
Jazz reported total revenues of $1.2 billion in Q3 2026, a 10% increase from the prior year period, which the release describes as a record quarterly level.
Why did Jazz report a net loss in the quarter?
The net loss reflects $754 million of acquired IPR&D expense tied to ABS-1230 from the Actio acquisition, which lowered results by $11.32 per share on a GAAP basis.
What did Jazz change in its 2026 guidance?
Jazz raised its full-year 2026 total revenue guidance to a range of $4.775 to $4.85 billion and updated its effective tax rate and GAAP SG&A expense guidance.
Historical context for JAZZ
Across the 29 sessions after earlier JAZZ headlines, the stock closed higher 18 times and lower 11 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | JAZZ | SPY |
|---|---|---|---|
| Nov 2, 2026 | Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 | -0.7% | -0.5% |
| Oct 23, 2026 | Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 | -0.3% | -0.5% |
| Oct 20, 2026 | Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 | +2.6% | +0.3% |
| Sep 30, 2026 | Citigroup initiated coverage on Jazz Pharma with a new price target | -0.4% | -0.2% |
| Sep 24, 2026 | Goldman resumed coverage on Jazz Pharma with a new price target | +0.6% | -0.1% |
| Sep 15, 2026 | Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences | -2.0% | -0.5% |
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2007
Follow JAZZ and get a push notification the moment its next story breaks.